John Libbey Eurotext

Magnesium Research


Magnesium sulphate activates the L-arginine/NO/cGMP pathway to induce peripheral antinociception in mice Volume 35, issue 1, January-February-March 2022


  • Figure 1.

  • Figure 2.

  • Figure 3.

  • Figure 4.

  • Figure 5.

  • Figure 6.

  • Figure 7.
Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Av. Antônio Carlos, 6627, 31.270-100, Belo Horizonte, Brazil
Correspondence: Department of Pharmacology, ICB-UFMG, Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG, Brazil, CEP: 31.270-901

In the present study, we investigated whether magnesium sulphate activates the L-arginine/NO/cGMP pathway and elicits peripheral antinociception. The male Swiss mice paw pressure test was performed with hyperalgesia induced by intraplantar injection of prostaglandin E2. All drugs were administered locally into the right hind paw of animals. Magnesium sulphate (20, 40, 80 and 160 μg/paw) induced an antinociceptive effect. The dose of 80 μg/paw elicited a local antinociceptive effect that was antagonized by the non-selective NOS inhibitor, L-NOArg, and by the selective neuronal NOS inhibitor, L-NPA. The inhibitors, L-NIO and L-NIL, selectively inhibited endothelial and inducible NOS, respectively, but were ineffective regarding peripheral magnesium sulphate injection. The soluble guanylyl cyclase inhibitor, ODQ, blocked the action of magnesium sulphate, and the cGMP-phosphodiesterase inhibitor, zaprinast, enhanced the antinociceptive effects of intermediate dose of magnesium sulphate. Our results suggest that magnesium sulphate stimulates the NO/cGMP pathway via neuronal NO synthase to induce peripheral antinociceptive effects.